Get the Stockscreener App
2.24
7.69%
0.16
After Hours:
2.22
-0.02
-0.89%
Adial Pharmaceuticals Inc stock is traded at $2.24, with a volume of 177.50K.
It is up +7.69% in the last 24 hours and up +41.77% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
See More
Previous Close:
$2.08
Open:
$2.08
24h Volume:
177.50K
Relative Volume:
1.20
Market Cap:
$4.80M
Revenue:
-
Net Income/Loss:
$-7.98M
P/E Ratio:
-0.2554
EPS:
-8.7693
Net Cash Flow:
$-6.49M
1W Performance:
+8.74%
1M Performance:
+41.77%
6M Performance:
-71.10%
1Y Performance:
-87.01%
1-Day Range:
$1.9501
$2.28
1-Week Range:
$1.94
$2.39
52-Week Range:
$1.31
$18.90
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
2.24 | 4.46M | 0 | -7.98M | -6.49M | -8.7693 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break - Bez Kabli
Adial Pharmaceuticals (ADIL) Drops 9.57% as Selling Pressure Mounts Near Key SupportShakeout Pattern - Newser
ADIL Q1 2026 Earnings: Narrowed Loss Beats Estimates, but Market Remains CautiousSocial Flow Trades - Newser
ADIL Q1 2026 Earnings: Narrowing Loss Beats Estimates, But Stock Declines Amid No RevenuePost-Earnings Reaction - Newser
Adial Pharmaceuticals lead drug fits new policy mood as bipartisan bill signals broader lens on alcohol use disorder - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Adial Pharmaceuticals, Inc. (ADIL) Stock Down Today? - Meyka
Why Is Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW) Stock Up Today? - Meyka
Armistice Capital/Steven Boyd report 4.99% stake in Adial (NASDAQ: ADIL) - Stock Titan
ADIL Should I Buy - Intellectia AI
Maxim Group Maintains Adial Pharmaceuticals(ADIL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Adial Pharmaceuticals 1Q Loss $2M >ADIL - Moomoo
The quiet strength in Adial Pharma (ADIL) business model (+4.20%) 2026-05-11Community Chart Signals - Newser
Adial Pharmaceuticals: Runway to Fund Operating Expenses Into 2nd Half of 2026 >ADIL - Moomoo
Adial Pharmaceuticals Q1 Net Income USD2 Million - TradingView
Adial Pharmaceuticals Reports Q1 2026 Results, Advances AD04 for Alcohol Use Disorder with FDA and European Developments 12 - Minichart
Adial Pharmaceuticals (NASDAQ: ADIL) details evolving AD04 development and IP - Stock Titan
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update - ChartMill
Adial Pharmaceuticals Q1 2026 10-Q Report: Clinical Development of AD04 for Alcohol Use Disorder, Financial Results, and Liquidity Update - Minichart
Adial Pharmaceuticals Inc (ADIL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Adial Pharmaceuticals Inc expected to post a loss of $1.21 a shareEarnings Preview - TradingView
Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Adial (NASDAQ: ADIL) flags going concern risk while advancing AD04 partnership plans - Stock Titan
ADIL Price Today: Adial Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
The quiet positioning of Adial Pharma (ADIL) nobody discusses (-10.13%) 2026-05-08Value ETF - Newser
EBIT per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
ADIL Stock Price, Quote & Chart | ADIAL PHARMACEUTICALS INC (NASDAQ:ADIL) - ChartMill
Adial Pharmaceuticals files patent application for AD04 By Investing.com - Investing.com South Africa
Adial Pharmaceuticals files patent application for AD04 - Investing.com
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 - The Manila Times
Adial seeks U.S. patent that could protect its lead alcohol-use drug to 2045 - Stock Titan
Adial Pharmaceuticals Files New U.S. Utility Patent Application For AD04 Targeting Alcohol Use Disorder - marketscreener.com
Exclusive: Adial Pharmaceuticals clears manufacturing milestone ahead of pivotal study for alcohol use disorder drug - MSN
Why did Adial Pharmaceuticals stock plunge over 20% after hours today? - MSN
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals (ADIL) Submits Application to FDA's National Priority Voucher Program - GuruFocus
Adial Pharmaceuticals applies for FDA priority voucher program - Investing.com
Adial Pharmaceuticals applies for FDA priority voucher program By Investing.com - Investing.com India
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program - The Manila Times
Adial Pharmaceuticals (ADIL) price target decreased by 10.26% to 23.80 - MSN
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug - Sahm
Adial Pharmaceuticals completes AD04 demonstration batch production By Investing.com - Investing.com Australia
ADIL (Adial Pharmaceuticals Inc) reports wider than expected Q4 2025 loss, yet stock notches 2.53 percent gain today.Quick Ratio - UBND thành phố Hải Phòng
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):